GO
Loading...

Enter multiple symbols separated by commas

Stocks Roche Holding AG

More

  • Lightning Round: It's too hot to touch Monday, 6 Apr 2015 | 6:51 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Biotech wins $45 million grant for Ebola vaccine Monday, 6 Apr 2015 | 9:28 AM ET
    Dr. Joseph Kim, founder of Inovio Pharmaceuticals

    Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.

  • March 27- Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares plunging 64 percent in premarket trading on Friday. The study tested the eye-drop solution, OHR-102, in combination with Roche Holding AG's injectable eye drug Lucentis, in patients with the wet...

  • March 27- Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares down 21 percent in premarket trading on Friday.

  • Drugs companies unite to mine genetic data Thursday, 26 Mar 2015 | 2:25 AM ET

    Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.

  • NEW YORK, March 22- As the dollar surged in the last 12 months, David Marcus, head of the Evermore Global Value fund, steadily increased his stake in Europe. Demand for a way to hedge currency exposure while investing in Europe helped the WisdomTree Europe Hedged Equity Fund bring in $5.3 billion in new assets over the first two months of the year, the most of any equity...

  • Cramer Remix: Cha-ching! Time to cash in Friday, 20 Mar 2015 | 7:26 PM ET
    Jim Cramer on the set of Mad Money

    “Mad Money” host Jim Cramer on why this rally won’t last forever and why you should take some off the table on this.

  • March 20- An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. Biogen is entering a field littered with...

  • Biogen Alzheimer's drug shows promise, shares up Friday, 20 Mar 2015 | 11:05 AM ET
    A multiple sclerosis drug manufactured at the Biogen Idec manufacturing plant in Cambridge, Mass.

    A Biogen Alzheimer's drug showed a significant slowing of the disease's hallmark cognitive declines.

  • Why biotech investors may be hurting innovation Friday, 13 Mar 2015 | 3:27 PM ET
    Biotech

    Over the past five years, investor money is increasingly moving toward consumer software and later-stage life science ventures, a trend that could help develop new treatments.

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • These 10 stocks could be due for a shake-up this year Wednesday, 4 Mar 2015 | 11:02 AM ET
    Exxon Mobil

    Data from eVestment show which stocks are poised to make a big run in 2015, based on the names institutional investors have already been trading.

  • Regeneron drug tops rivals in some vision loss cases Wednesday, 18 Feb 2015 | 5:00 PM ET
    Eye examination

    Regeneron Pharmaceuticals' top-selling eye drug, Eylea, bested Roche's Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss.

  • European stocks end mixed, Greek banks tank Wednesday, 28 Jan 2015 | 11:34 AM ET

    European markets ended mixed on Wednesday after seesawing for much of the session, with indexes pressures by a staggering slump in Greek bank stocks.

  • Meet Morningstar's fund managers of the year Wednesday, 21 Jan 2015 | 5:42 PM ET
    Stock performance chart on computer screen

    Here are the fund managers Morningstar considers the best of the best.

  • Swiss large-caps lose $100B on currency move Thursday, 15 Jan 2015 | 8:45 AM ET

    The Swiss franc soared—and Swiss stocks tanked—as that country's central bank shocked markets Thursday with a move to scrap a cap against the euro.

  • US stocks end lower with crude; Alcoa reports Monday, 12 Jan 2015 | 4:08 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks dropped Monday after a second weekly loss.

  • $1.8B drug deal to target cancer at genetic level Monday, 12 Jan 2015 | 8:05 AM ET

    Foundation Medicine CEO Michael Pellini tells CNBC, "It's an important day for patients battling cancer."

  • Great day for Foundation Medicine: CEO Monday, 12 Jan 2015 | 7:29 AM ET
    Great day for Foundation Medicine: CEO

    CNBC's Meg Tirrell, and Michael Pellini, Foundation Medicine president & CEO, discuss the benefits of Roche's majority stake in Foundation Medicine.

  • Goldman Sachs: Watch out for energy M&A in 2015 Monday, 12 Jan 2015 | 7:14 AM ET
    A derrick hand removes the the plastic caps off the threaded ends of pipe used in the drilling process in Knox County, Ohio.

    Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.